Xenon Pharmaceuticals INC 10-Q quarterly reports

Xenon Pharmaceuticals Inc. reported substantial net losses and highlighted the critical need for future funding to advance its neuroscience-focused drug development programs, particularly for azetukalner.

Xenon Pharmaceuticals Inc. reported strong Q1 2026 results, with positive Phase 3 data for azetukalner in focal onset seizures and significant capital raised, positioning the company for future growth.

Xenon Pharmaceuticals Inc. reported a wider net loss in Q3 2025 as it significantly increased R&D spending to advance multiple late-stage clinical programs, including azetukalner for epilepsy and depression.

Xenon Pharmaceuticals Inc. reported a significantly wider net loss in Q2 2025 as research and development expenses surged for its late-stage clinical programs, despite a milestone payment from a collaboration.

Xenon Pharmaceuticals reports a net loss of $65.0 million for Q1 2025, with collaboration revenue of $7.5 million driven by a milestone payment from Neurocrine Biosciences.

Xenon Pharmaceuticals reported a net loss of $62.8 million for the third quarter of 2024, while advancing its clinical programs for azetukalner and other pipeline candidates.

Xenon Pharmaceuticals reports a net loss of $105.9 million for the first six months of 2024, while advancing its clinical programs and early-stage pipeline.

Xenon Pharmaceuticals reported a net loss of $47.9 million for the first quarter of 2024, while advancing its clinical programs and drug discovery efforts.